Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8366305 | 0.97 | CA1 (0.58) | CA1CA2HRH3USP2TSHR | |
| SCHEMBL18828734 | 0.97 | CA1 (0.58) | CA1CA2HRH3USP2TSHR | |
| SCHEMBL8370841 | 0.97 | CA1 (0.58) | CA1CA2HRH3USP2TSHR | |
| SCHEMBL2583782 | 0.97 | CA1 (0.58) | CA1CA2HRH3USP2TSHR | |
| SCHEMBL14779905 | 0.97 | CA1 (0.58) | CA1CA2HRH3USP2TSHR | |
| SCHEMBL17088827 | 0.97 | CA1 (0.58) | CA1CA2HRH3USP2TSHR | |
| SCHEMBL275547 | 0.97 | CA1 (0.58) | CA1CA2HRH3USP2TSHR | |
| SCHEMBL28839918 | 0.95 | CA1 (0.56) | CA1CA2HRH3USP2TSHR | |
| SCHEMBL3815211 | 0.94 | — | — | |
| SCHEMBL10727963 | 0.91 | CA1 (0.52) | CA1CA2HRH3ACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11199525-A | — | — | None | — | — | JP | disclosed |
| EP-4568948-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| WO-2024059010-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023168686-A1 | SUBSTITUTED CYCLOPENTANES AS CDK2 INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2023-09-14 | — | — | WO | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2022121844-A1 | DIHYDROPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-16 | — | — | WO | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-4588743-A | CARDIOVASCULAR AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1986-05-13 | — | — | US | disclosed |
| US-4582854-A | BRONCHODILATOR, ANTIINFLAMMATORY AGENT, ANALGESIC | E. R. SQUIBB & SONS, INC. (US) | 1986-04-15 | — | — | US | disclosed |
| US-4575512-A | THROMBOXANE SYNTHETASE INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1986-03-11 | — | — | US | disclosed |
| EP-0163562-A1 | 7-Oxabicycloheptane substituted ethers | E.R. Squibb & Sons, Inc. (US) | 1985-12-04 | — | — | EP | disclosed |
| EP-0161904-A2 | Tetrahydrofuranyl and tetrahydrothienyl substituted ethers | E.R. Squibb & Sons, Inc. (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4550120-A | BRONCHODILATOR AGENTS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1985-10-29 | — | — | US | disclosed |
| US-4542151-A | CARDIOVASCULAR, BRONCHODILATION, ANALGESICS, ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1985-09-17 | — | — | US | disclosed |
| US-4521539-A | ANALGESICS, CARDIONVASCULAR AND ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-06-04 | — | — | US | disclosed |
| US-4454274-A | Aminoplast curable coating compositions containing cycloaliphatic sulfonic acid esters as latent acid catalysts | PPG INDUSTRIES, INC. (US) | 1984-06-12 | — | — | US | disclosed |
| US-4237138-A | REGULATORS OF CARDIOVASCULAR SYSTEM | PFIZER INC. (US) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | CA1 3051/4885CA2 3567/4885HRH3 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.